Review for "Genetic Variations and Clinical Spectrum of Dystroglycanopathy in a Large Cohort of Chinese Patients"

2020 ◽  
pp. jmedgenet-2019-106671
Author(s):  
Yanbin Fan ◽  
Dandan Tan ◽  
Danyu Song ◽  
Xu Zhang ◽  
Xingzhi Chang ◽  
...  

BackgroundLMNA-related muscular dystrophy is caused by mutations in LMNA gene. We aimed to identify genetic variations and clinical features in a large cohort of Chinese patients with LMNA mutations in an attempt to establish genotype-phenotype correlation.MethodsThe clinical presentations of patients with LMNA-related muscular dystrophy were recorded using retrospective and prospective cohort study. LMNA mutation analysis was performed by Sanger sequencing or next-generation sequencing. Mosaicism was detected by personal genome machine amplicon deep sequencing for mosaicism.ResultsEighty-four patients were identified to harbour LMNA mutations. Forty-one of those were diagnosed with LMNA-related congenital muscular dystrophy (L-CMD), 32 with Emery-Dreifuss muscular dystrophy (EDMD) and 11 with limb-girdle muscular dystrophy type 1B (LGMD1B). We identified 21 novel and 29 known LMNA mutations. Two frequent mutations were identified: c.745C>T and c.1357C>T. A correlation between the location of mutation and the clinical phenotype was observed: mutations affecting the head and coil 2A domains mainly occurred in L-CMD, while the coil 2B and Ig-like domains mainly related to EDMD and LGMD1B. We found somatic mosaicism in one parent of four probands. Muscle biopsies revealed 11 of 20 biopsied L-CMD exhibited inflammatory changes, and muscle cell ultrastructure showed abnormal nuclear morphology.ConclusionsOur detailed clinical and genetic analysis of 84 patients with LMNA-related muscular dystrophy expands clinical spectrum and broadens genetic variations caused by LMNA mutations. We identified 21 novel and 29 known LMNA mutations and found two frequent mutations. A correlation between the location of mutation and the clinical severity was observed. Preliminary data suggested that low-dose corticosteroid treatment may be effective.


2020 ◽  
Author(s):  
Danyu Song ◽  
Yi Dai ◽  
Xiaoyu Chen ◽  
Xiaona Fu ◽  
Xingzhi Chang ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 375.2-375
Author(s):  
O. Argyropoulou ◽  
V. Pezoulas ◽  
L. Quartuccio ◽  
F. Ferro ◽  
S. Gandolfo ◽  
...  

Background:Cryoglobulinemic vasculitis (CV) is a serious complication of Sjögren’s syndrome (SS) and is closely associated with type II IgMk cryoglobulins. CV has been well documented in HCV patients without SS, and shares common features with CV in SS. So far, few studies have described the clinical picture of CV in HCV negative SS, but the number of studied patients was rather small and CV was not well defined. To better describe the clinical spectrum of CV in SS and explore the differences compared to HCV-related CV, a large cohort of well characterized patients is required.Objectives:To study the clinical phenotype of CV in HCV-negative SS patients, in a large cohort of well characterized patients, after applying stringent classification CV criteria and in comparison with the classical CV of HCV patients.Methods:From a total cohort of 1997 consecutive SS patients who fulfill the 2016 EULAR/ACR criteria and are followed up in 5 clinical centers ([Universities ofUdine,Pisa andAthens,Harokopio andIoannina, (UPAHI)], those who fulfil the 2011 classification criteria for CV were identified and compared with matched HCV-CV patients according to age and gender. Glandular, extra-glandular manifestations and serologic features were compared between the 2 CV groups. Statistical analysis for categorical variables was performed by Fisher exact or chi-square tests and for continuous variables with t test or Mann-Whitney accordingly.Results:Among the 1083 SS patients who have been evaluated for cryoglobulins, 114 (9,8%) were found positive. Seventy-one (6,5%) SS patients met the 2011 CV criteria while 44 patients presented with type II IgMk cryoglobulinemia without CV. Sixty nine of 71 (97%) SS related CV patients were females and 2 of 71 (3%) males. Forty eight of 71 (68%) had SS disease onset >35 and <65 years old while 14/71 (19,7%) and 9/71 (12,7%) had SS disease onset <35 and >65 years old respectively. The most common clinical manifestations of CV among SS patients were purpura (90%) followed by arthralgias (70%), fatigue (59%), Raynaud’s phenomenon (48%), lymphadenopathy (31%), peripheral neuropathy (22,3%), vasculitic ulcer (11,3%) and glomerulonephritis (11,3%). Interestingly, almost 50% of SS related CV patients developed lymphoma and displayed high frequency of strong predictors including purpura, low C4 complement (88,6%) and salivary gland enlargement (SGE). Compared to HCV-CV patients, SS-CV patients had higher frequency of sicca manifestations, SGE, fatigue, arthritis, Raynaud’s phenomenon, lymphadenopathy, type II IgMk cryoglobulins and lymphoma.Conclusion:The prevalence of cryoglobulinemia and CV among SS patients is about 10% and 6-7% respectively. SS-CV patients are mainly middle-aged females with purpura as the main clinical manifestation, and up to one half of them may develop lymphoma, which is rarer in HCV-CV. Compared to HCV-CV patients, SS patients with CV have more frequently sicca symptoms, SGE and type II IgMk cryoglobulins.Disclosure of Interests:Ourania Argyropoulou: None declared, Vasileios Pezoulas: None declared, Luca Quartuccio: None declared, Francesco Ferro: None declared, Saviana Gandolfo: None declared, Valentina Donati: None declared, Aliki Venetsanopoulou: None declared, Loukas Chatzis: None declared, Evangelia Zampeli: None declared, Maria Mavromati: None declared, Paraskevi Voulgari: None declared, Clio Mavragani: None declared, Chiara Baldini: None declared, Fotini Skopouli: None declared, Dimitris Fotiadis: None declared, Massimo Galli: None declared, Salvatore De Vita Consultant of: Roche, Human Genome Science, Glaxo Smith Kline and Novartis, Haralampos M. Moutsopoulos: None declared, Andreas Goules: None declared, Athanasios Tzioufas: None declared


2020 ◽  
Author(s):  
Bei Cao ◽  
Xiaojing Gu ◽  
Qianqian Wei ◽  
Chunyu Li ◽  
Yongping Chen ◽  
...  

Abstract Objective Glycosyltransfersase 8 domain containing 1 ( GLT8D1 ) gene was identified to be an amyotrophic lateral sclerosis (ALS) causative gene via pedigree co-segregation and burden analysis. However, validations based on large cohort of ALS among different ethnic population are essential. We aimed to systematically screen all exons of GLT8D1 in a large cohort of Chinese ALS patients, study the genotype-phenotype correlation and explore the role of rare variants of GLT8D1 in ALS.Methods A total of 977 sporadic ALS (sALS) and 47 familial ALS (fALS) cases underwent whole exome sequencing. Rare variants with MAF<0.1% in GLT8D1 were analyzed. Moreover, by using the controls from gnomAD database, rare variants were included in the burden analysis via 5 different algorithms.Results We identified 1 likely pathogenic variant in the exon 4 of GLT8D1 in a fALS case and validated within the pedigree. Moreover, 3 variant of uncertain significance (VUS) in 4 patients among the 977 sALS cases 1 VUS in 1 case among the 47 fALS cases were also identified. Furthermore, in the burden analysis, there were no significant enrichment of rare variants of GLT8D1 in the whole gene level or exon 4 exclusively among Chinese patients with sALS.Conclusion Cosegregation findings in our study further supported the pathogenic role of GLT8D1 in fALS. However, no pathogenic mutation was identified in the sALS patients, and rare variants were not enriched in the whole gene level or exon 4 of GLT8D1 among sALS patients, both of which suggested that the GLT8D1 may not play a role in Chinese patients with sALS.


Sign in / Sign up

Export Citation Format

Share Document